Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechlorethamine 0.04% in MF Non-Responders
NCT00535470Phase 2Completed
- Sponsor
- Ceptaris Therapeutics
- Start
- Jul 2007
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mechlorethamine in mycosis fungoides (MF), sponsored by Ceptaris Therapeutics. Primary endpoint: Response Rate at 7 months. Started Jul 2007; status: completed.
02
Drugs
mechlorethamine
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT00535470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00535470.